

Date and Time: 19th June 2012, 10:30-16:30

Place: NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

Present: GDG

1. Howard Thomas (Chair)	HT
2. Elizabeth Boxall	EB
3. Javier Vilar	JV
4. Angela Narbey	AN
5. Alan Mitchell	AM
6. Gareth Tudor-Williams (present for notes 1 – 6)	GTW
7. Emily Lam	EL
8. Patrick Kennedy (present for notes 6-11)	PK
9. Joyeta Das	JD

NCGC Technical team

10. Gill Ritchie	GR
11. Grammati Sarri	GS
12. Rosa Lau	RL
13. Sarah Bermingham	SB
14. Amy Kelsey	AK
15. Grant Hill-Cawthorne	GHC
16. Ralph Hughes	RH

NICE

17. Sarah Dunsdon	SD
-------------------	----

Apologies

18. Geoffrey Dusheiko	GD
19. Aftab Ala	AA
20. Sarah Wise	SW

Notes

Minutes: confirmed

Hepatitis B GDG Meeting 8

1. The Chair welcomed everyone to the Hepatitis B Guideline Development Group (GDG) meeting 8. Apologies were received from Geoffrey Dusheiko, Aftab Ala and Sarah Wise. Apologies were received from Patrick Kennedy for the morning of the meeting, he arrived at 12pm. Gareth Tudor-Williams gave apologies for the second half of the meeting, he left the meeting at 1:30pm. The Chair then introduced Ralph Hughes, NCGC Acting Senior Health Economist, to the group. Ralph introduced himself and informed the group that he had been working with Sarah on the health economic model and would be presenting at this meeting.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role). The following declarations of interest were made:

EB declared a personal pecuniary interest; she received a fee for talking about the epidemiology of hepatitis b at a meeting of hepatitis nurses. The meeting was sponsored by Bristol Myers Squibb who develop entecavir.

JV declared a personal pecuniary interest; he spoke at a non promotional Bristol Myers Squibb meeting, presenting clinical cases only. He received an honorarium for this talk. He also declared a personal non-pecuniary interest; he is the secondary care doctor on a testing project which has gained a Gilead fellowship sponsoring (competitive national funding source).

EL declared a personal non-pecuniary interest; she has become a patient member on a Gilead funded HBV testing project in Manchester. No financial rewards are involved.
3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Rosa Lau, NCGC Research Fellow, who gave a presentation on the clinical effectiveness of prophylactic treatment in reducing risk of hepatitis b virus reactivation and severity of flares in people who are immunocompromised. The Chair thanked RL for her presentation.
5. The Chair then introduced Sarah Bermingham, NCGC Acting Senior Health Economist, who gave a presentation on the cost effectiveness of prophylactic treatment in reducing risk of hepatitis b virus reactivation and severity of flares in people who are immunocompromised. The Chair thanked SB for her presentation.
6. The GDG then discussed the evidence presented and drafted recommendations.
7. SB and RH then discussed the baseline natural history transition probabilities of the Health Economic Model and the antiviral sequences and combinations in HBeAg positive and HBeAg negative model with the GDG. The Chair thanked SB and RH for their presentation.

Notes

8. The Chair then introduced Grammati Sarri, NCGC Senior Research Fellow, who presented the results of the lamivudine resistant adults with HBeAg positive chronic hepatitis b infection and nucleoside naïve adults with HBeAg negative chronic hepatitis b infection network meta analyses. The Chair thanked GS for her presentation.
9. GS and RL then led discussion with the GDG on the research protocol for 1 clinical question. The following protocol was agreed and signed off by the GDG: what are the information needs of patients with chronic hepatitis b and their carers?
10. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

11. Tuesday 24th July 2012, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.